{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.756","value":"4.54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Week +4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.807","value":"4.62"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Week +8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.667","value":"6.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Week +16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.564","value":"6.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Week +24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.923","value":"5.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Week +28"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.006","value":"4.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Week +52"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.119","value":"8.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"title":"Week 92"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.085","value":"6.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Week 104"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.983","value":"4.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"title":"Week 117"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.047","value":"4.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"title":"Week 130"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.798","value":"3.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"title":"Week 143"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.221","value":"2.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"title":"Week 156"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.731","value":"4.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Week 169"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.673","value":"2.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"title":"Week 182"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.286","value":"5.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"title":"Week 195"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.099","value":"5.35"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"title":"Week 208"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.701","value":"7.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"title":"Week 221"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.342","value":"5.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"title":"Week 234"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.427","value":"4.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Week 247"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"EQ-5D-5L is a standardized instrument for measuring health outcomes in a wide range of health conditions and treatments. It consists of visual analogue scale (EQ VAS) which records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'Best imaginable health state' and 'worst imaginable health state'. The EQ VAS scores were anchored on 100 = the best health you can imagine and 0 = worst health you can imagine.","dispersionType":"Standard Deviation","groups":[{"description":"Participants randomized to the BAT arm, who crossed over and received at least one dose of ruxolitinib","id":"OG000","title":"Best Available Therapy (BAT)"}],"paramType":"MEAN","populationDescription":"Cross-over set consisted of all participants randomized to the BAT arm, who crossed over and received at least one dose of ruxolitinib.","reportingStatus":"POSTED","timeFrame":"Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28, 52, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247 after cross-over","title":"Change From Baseline in EQ-5D-5L VAS, by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover","type":"SECONDARY","unitOfMeasure":"Score on a scale"}